In this free webinar, clinical and oncology experts will discuss challenges to consider when pursuing immuno-oncology development, including complexity in trial design, competition for patients and sites, the potential for overlapping toxicities, the selection of biomarkers, and commercial risks as the standard of care (SOC) evolves rapidly. Attendees will also hear recommendation streamline development and support commercial success.
TORONTO (PRWEB) May 29, 2020
It’s been almost a decade since the US Food and Drug Administration (FDA) approved the first checkpoint inhibitor, Bristol Myers Squibb’s YERVOY® (ipilimumab) in 2011. In recent years, the number of clinical trials involving checkpoint inhibitors and other immuno-oncology (IO) therapies has been increasing as Sponsors investigate their use in combination with one another, with radiotherapy, chemotherapies, targeted therapies, cancer vaccines and oncolytic viruses.
Despite the benefits that these combination approaches promise to patients, the sheer number of potential therapies, combinations, and administration regimens poses challenges for Sponsors. In this free webinar, clinical and oncology experts will highlight issues that Sponsors face in planning and executing combination IO therapy trials and share strategies for delivering a more intentional approach and choice of combinations for hypothesis testing.
Join Jennifer Harris, Vice President, Clinical Development Oncology and Global Head of Immuno-Oncology, Syneos Health, Jessica Lee, Managing Director, Consulting, Syneos Health and Francesca Zolezzi, Director, Molecular Profiling, Translational Sciences, Syneos Health in a live webinar and open question and answer discussion on Friday, June 12, 2020 at 10am EDT (3pm BST/UK).
For more information or to register for this event, visit The Changing Face of Immuno-Oncology Development.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
For the original version on PRWeb visit: https://www.prweb.com/releases/the_changing_face_of_immuno_oncology_development_upcoming_webinar_hosted_by_xtalks/prweb17155053.htm